Impact of stereotactic radiosurgery dose on control of cerebral metastases from renal cell carcinoma
Standard
Impact of stereotactic radiosurgery dose on control of cerebral metastases from renal cell carcinoma. / Rades, Dirk; Huttenlocher, Stefan; Gebauer, Niklas; Hornung, Dagmar; Trang, Ngo Thuy; Khoa, Mai Trong; Schild, Steven E.
in: ANTICANCER RES, Jahrgang 35, Nr. 6, 06.2015, S. 3571-4.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Impact of stereotactic radiosurgery dose on control of cerebral metastases from renal cell carcinoma
AU - Rades, Dirk
AU - Huttenlocher, Stefan
AU - Gebauer, Niklas
AU - Hornung, Dagmar
AU - Trang, Ngo Thuy
AU - Khoa, Mai Trong
AU - Schild, Steven E
N1 - Copyright© 2015 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved.
PY - 2015/6
Y1 - 2015/6
N2 - AIM: Renal cell carcinoma (RCC) is a relatively radioresistant tumor and may require for higher radiation doses than other tumor types.PATIENTS AND METHODS: Nineteen patients treated with 20 Gy of stereotactic radiosurgery (SRS) alone for one to three cerebral metastases were compared to nine patients treated with 16-18 Gy.RESULTS: SRS with 20 Gy led to significantly better local control than did 16-18 Gy (81% vs. 50% at 12 months; p<0.001). Results were also significant on multivariate analysis (risk ratio: 6.30; p=0.033). SRS dose did not associate with freedom from new cerebral metastases (75% vs. 62% at 12 months; p=0.42) or survival (16% vs. 56% at 12 months; p=0.46). On multivariate analyses, better survival was associated with higher Karnofsky performance score (p<0.001) and absence of extracranial metastatic disease (p=0.006).CONCLUSION: In patients treated with SRS alone, local control of cerebral metastases from RCC was better after 20 Gy than after 16-18 Gy.
AB - AIM: Renal cell carcinoma (RCC) is a relatively radioresistant tumor and may require for higher radiation doses than other tumor types.PATIENTS AND METHODS: Nineteen patients treated with 20 Gy of stereotactic radiosurgery (SRS) alone for one to three cerebral metastases were compared to nine patients treated with 16-18 Gy.RESULTS: SRS with 20 Gy led to significantly better local control than did 16-18 Gy (81% vs. 50% at 12 months; p<0.001). Results were also significant on multivariate analysis (risk ratio: 6.30; p=0.033). SRS dose did not associate with freedom from new cerebral metastases (75% vs. 62% at 12 months; p=0.42) or survival (16% vs. 56% at 12 months; p=0.46). On multivariate analyses, better survival was associated with higher Karnofsky performance score (p<0.001) and absence of extracranial metastatic disease (p=0.006).CONCLUSION: In patients treated with SRS alone, local control of cerebral metastases from RCC was better after 20 Gy than after 16-18 Gy.
KW - Aged
KW - Brain Neoplasms
KW - Carcinoma, Renal Cell
KW - Female
KW - Humans
KW - Kaplan-Meier Estimate
KW - Karnofsky Performance Status
KW - Male
KW - Middle Aged
KW - Neoplasms, Radiation-Induced
KW - Proportional Hazards Models
KW - Radiosurgery
KW - Radiotherapy Dosage
M3 - SCORING: Journal article
C2 - 26026128
VL - 35
SP - 3571
EP - 3574
JO - ANTICANCER RES
JF - ANTICANCER RES
SN - 0250-7005
IS - 6
ER -